

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
HIGHLY SPECIALISED TECHNOLOGIES EVALUATION PROGRAMME**

Equality impact assessment – Scoping

**HST Cerliponase alfa for treating neuronal ceroid
lipofuscinosis type 2 (CLN2)**

Batch 50

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Consultees noted that if the indication was limited to people with only early-stages of the disease, people with more advanced disease may be excluded.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The population in scope covers the full marketing authorisation for the drug. If the recommendation were to restrict access to the drug by disease stage or progression, the committee would need to consider whether its recommendation could have a differential impact on people protected by equality legislation than on the wider population

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues

been identified during the scoping process, and, if so, have changes to the matrix been made?
No

Approved by Associate Director (name): ...Sheela Upadhyaya ...
Date: 07/08/2017